EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 765 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR Cancer in My Community: Overcoming Inequities in Care in Argentina January 3, 2023 EMA Recommends Extension of Therapeutic Indications for Nivolumab July 1, 2021 First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... February 17, 2025 Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Load more HOT NEWS Children with Acute Lymphoblastic Leukemia Can Skip Radiation to the Brain Cancer Rehabilitation Starts at Diagnosis: Part II Airbrushed Magazines Hurt the Body Image of Young Women — Here’s... Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to...
